Corcept Therapeutics CORT Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corcept Therapeutics's accrued expenses?
- Corcept Therapeutics (CORT) reported accrued expenses of $80.16M in Q1 2026.
- How has Corcept Therapeutics's accrued expenses changed year-over-year?
- Corcept Therapeutics's accrued expenses decreased by 9.8% year-over-year, from $88.88M to $80.16M.
- What is the long-term trend for Corcept Therapeutics's accrued expenses?
- Over 5 years (2020 to 2025), Corcept Therapeutics's accrued expenses has grown at a 33.7% compound annual growth rate (CAGR), from $21.19M to $90.6M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.